Undoubtedly, in the course of CKD, elevations in circulating ACE2 activity provide a novel biomarker of the failure of vitamin D/calcitriol interventions to effectively suppress the deleterious effects of ADAM17 and RAS hyperactivation. Here, ACE2 is linked to chronic kidney disease.